VANCOUVER, British Columbia, April 7, 2004 (PRIMEZONE) -- Dr. John Todd, president of ProtoKinetix, Inc. (OTCBB:PKTX), is pleased to announce that Dr. Jean-Marie Dupuy has accepted a position on the ProtoKinetix Board of Directors. Dr. Dupuy will be responsible for the Company's medical research efforts and is currently in Paris working with the Georges Pompidou Hospital on the clinical evaluation trials for the BioCurex (OTCBB:BOCX) RECAF molecule. As Medical Research Director, Jean-Marie will consult with major European institutions concerning potential product collaboration. The following abbreviated resume will serve to outline the qualifications of this internationally acclaimed medical scientist.
Jean-Marie Dupuy, M.D., is a consultant to several pharmaceutical companies and biotech companies for project development, scientific advice, pre-clinical and clinical research, clinical trial implementation, and regulatory agency assistance. Prior to working as a consultant, Dr. Dupuy was Vice President in charge of Medical & Regulatory Affairs at Immuno-designed Molecules (1998 -2002), Project Director, Immunology/Oncology Programs at Wyeth Ayerst (1994 -98) and Medical Director at Pasteur Merieux Connaught (1986 -94).
Prior to joining the pharmaceutical industry, Dr. Dupuy held several academic positions in France and Canada. In Canada, he was Director of clinical immunology, Montreal Children's Hospital and Director of the Immunology Research Center, Armand Frappier Institute, Montreal, Canada (1978 -86). In France, Dr. Dupuy was Deputy Director of the Department of Paediatric Liver Diseases, Bicetre Children Hospital, Paris and head of the Immunology and Virology Research Centre (1970-78) at Bicetre. Dr Dupuy has conducted intensive clinical & research activities in Paediatrics, Immunology, Virology and Vaccines. He received his post-doctoral training in Minneapolis (USA).
Dr. Dupuy is the author or co-author of more than 240 original scientific and medical articles, communications and books.
About ProtoKinetix:
ProtoKinetix Inc. is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies. The company is focused on a new generation of monoclonal antibodies termed "Super-Antibodies". These antibodies are engineered to provide higher potency and resiliency resulting in vastly enhanced therapeutic impact. ProtoKinetix will use this technology to create therapeutic antibodies to help in the treatment of cancer.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President